At Day 21, low-dose ketamine KET01 shows no statistical edge over placebo.

Ketabon GmbH revealed positive top-line results from its phase 2 KET01-02 study investigating KET01, an oral slow-release formulation of oral ketamine, for treatment-resistant depression (TRD). Results were promising initially. Investigators noted improvements in depression severity as early as day 4, but data were not statistically significant over placebo at day 21.

A look at Ketabon GmbH’s KET01-02 study in treatment-resistant depression

The trial studied KET01 doses of 120 mg and 240 mg per day. It involved 122 individuals who were outpatients with current major depressive episodes not responding to at least two standard antidepressants. Participants received KET01 once daily in addition to a traditional antidepressant treatment over the three-week period. In particular, the 240 mg/day dose showed clinically relevant improvements with statistical significance versus placebo on days 4 and 7. The drug, however, did not maintain significance at day 21.


Read more
  • 0

Lilly publishes promising phase 2 trial data for retatrutide, a potential obesity therapy

Lilly has announced promising data from its NCT 04881760 phase 2 study of retatrutide, a potential obesity drug. The drug candidate, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1 and glucagon receptors, was associated with significant weight loss, improved glycemic control and cardiovascular health.

At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for efficacy in participants with obesity or overweight without diabetes. Participants had a mean weight reduction of up to 17.5% (41.2 lb) at 24 weeks. That figure increased to 24.2% at 48 weeks.

The double-blind, randomized, placebo-controlled study enrolled 338 adults with obesity or overweight and related health conditions to assess the drug’s efficacy, side effects, and safety. Data from that study were published in NEJM.

Lancet recently published data from the separate phase 2 NCT04867785 study on  retatrutide, in…

Read more
  • 0